Company Interview / A healing hand for stroke victims

Dr Liz Dallimore, chief executive of Argenica Therapeutics, outlines how the company is positioning its lead neuroprotective peptide ARG-007 to target stroke and traumatic brain injury patients. Dallimore states that the phase 2 stroke trial meets its primary safety endpoint, which she views as critical in neurology. While the overall secondary endpoint of infarct volume reduction is not achieved across all patients, she points to a strong efficacy signal in a subgroup of moderate to severe stroke patients.

Dallimore explains that patients with poor collateral blood flow usually experience rapid expansion of brain injury, but data from this subgroup reportedly show statistically significant prevention of infarct expansion in those receiving ARG-007. She claims this translates into more patients walking independently, which she regards as a major quality-of-life outcome and a key focus for the next phase of trials.

Looking ahead, Dallimore says 2026 milestones include launching a phase 2b stroke trial under an investigational new drug application with the FDA, opening sites in the US and Australia, completing commercial-scale manufacturing, and initiating a phase 1b traumatic brain injury study locally. She adds that Argenica Therapeutics (ASX:AGN) is in active dialogue with several global and mid-tier pharma companies on potential licensing, while managing cash burn carefully and exploring non-dilutive funding.

*partner content